Categories
- Global News Feed
- Uncategorized
- Alabama Stem Cells
- Alaska Stem Cells
- Arkansas Stem Cells
- Arizona Stem Cells
- California Stem Cells
- Colorado Stem Cells
- Connecticut Stem Cells
- Delaware Stem Cells
- Florida Stem Cells
- Georgia Stem Cells
- Hawaii Stem Cells
- Idaho Stem Cells
- Illinois Stem Cells
- Indiana Stem Cells
- Iowa Stem Cells
- Kansas Stem Cells
- Kentucky Stem Cells
- Louisiana Stem Cells
- Maine Stem Cells
- Maryland Stem Cells
- Massachusetts Stem Cells
- Michigan Stem Cells
- Minnesota Stem Cells
- Mississippi Stem Cells
- Missouri Stem Cells
- Montana Stem Cells
- Nebraska Stem Cells
- New Hampshire Stem Cells
- New Jersey Stem Cells
- New Mexico Stem Cells
- New York Stem Cells
- Nevada Stem Cells
- North Carolina Stem Cells
- North Dakota Stem Cells
- Oklahoma Stem Cells
- Ohio Stem Cells
- Oregon Stem Cells
- Pennsylvania Stem Cells
- Rhode Island Stem Cells
- South Carolina Stem Cells
- South Dakota Stem Cells
- Tennessee Stem Cells
- Texas Stem Cells
- Utah Stem Cells
- Vermont Stem Cells
- Virginia Stem Cells
- Washington Stem Cells
- West Virginia Stem Cells
- Wisconsin Stem Cells
- Wyoming Stem Cells
- Biotechnology
- Cell Medicine
- Cell Therapy
- Diabetes
- Epigenetics
- Gene therapy
- Genetics
- Genetic Engineering
- Genetic medicine
- HCG Diet
- Hormone Replacement Therapy
- Human Genetics
- Integrative Medicine
- Molecular Genetics
- Molecular Medicine
- Nano medicine
- Preventative Medicine
- Regenerative Medicine
- Stem Cells
- Stell Cell Genetics
- Stem Cell Research
- Stem Cell Treatments
- Stem Cell Therapy
- Stem Cell Videos
- Testosterone Replacement Therapy
- Testosterone Shots
- Transhumanism
- Transhumanist
Archives
Recommended Sites
Category Archives: Global News Feed
Spero Therapeutics Announces SPR720 Phase 2a Interim Results and Provides a Business Update
Posted: October 30, 2024 at 2:42 am
Phase 2a proof-of-concept study of SPR720 for the treatment of Nontuberculous Mycobacterial Pulmonary Disease (NTM-PD) did not meet its primary endpoint, based on planned interim analysis of 16 patients
Read the original here:
Spero Therapeutics Announces SPR720 Phase 2a Interim Results and Provides a Business Update
Posted in Global News Feed
Comments Off on Spero Therapeutics Announces SPR720 Phase 2a Interim Results and Provides a Business Update
BioVie Inc. Announces Closing of Registered Direct Offering
Posted: October 30, 2024 at 2:42 am
CARSON CITY, Nev., Oct. 29, 2024 (GLOBE NEWSWIRE) -- BioVie Inc. (Nasdaq: BIVI), (“BioVie” or the “Company”), a clinical-stage company developing innovative drug therapies to treat chronic debilitating conditions including liver disease and neurological and neuro-degenerative disorders, today announced the closing of its previously announced registered direct offering of 1,146,000 shares of its common stock priced at-the-market under Nasdaq rules at a price of $2.83 per share.
See the article here:
BioVie Inc. Announces Closing of Registered Direct Offering
Posted in Global News Feed
Comments Off on BioVie Inc. Announces Closing of Registered Direct Offering
Cytek Biosciences to Report Third Quarter 2024 Financial Results on November 5, 2024
Posted: October 30, 2024 at 2:42 am
FREMONT, Calif., Oct. 29, 2024 (GLOBE NEWSWIRE) -- Cytek Biosciences, Inc. (Nasdaq: CTKB), a leading cell analysis solutions company, today announced it will report financial results for the third quarter 2024 after market close on Tuesday, November 5, 2024. The company’s management will webcast a corresponding conference call beginning at 1:30 p.m. Pacific Time / 4:30 p.m. Eastern Time to discuss its results, business developments and outlook.
Continued here:
Cytek Biosciences to Report Third Quarter 2024 Financial Results on November 5, 2024
Posted in Global News Feed
Comments Off on Cytek Biosciences to Report Third Quarter 2024 Financial Results on November 5, 2024
Shuttle Pharma Pays Off Senior Secured Convertible Note
Posted: October 30, 2024 at 2:42 am
GAITHERSBURG, Md., Oct. 29, 2024 (GLOBE NEWSWIRE) -- Shuttle Pharmaceuticals Holdings, Inc. (Nasdaq: SHPH) (“Shuttle Pharma”), a discovery and development stage specialty pharmaceutical company focused on improving outcomes for cancer patients treated with radiation therapy (RT), today announced that, during the third quarter of this year, it paid off the entirety of the outstanding balance due under its Senior Secured Convertible Note (“Note”) issued on January 11, 2023.
Continue reading here:
Shuttle Pharma Pays Off Senior Secured Convertible Note
Posted in Global News Feed
Comments Off on Shuttle Pharma Pays Off Senior Secured Convertible Note
ADMA Biologics to Report Third Quarter 2024 Financial Results on November 7, 2024
Posted: October 30, 2024 at 2:42 am
Conference Call Scheduled for November 7, 2024, at 4:30 p.m. ET Conference Call Scheduled for November 7, 2024, at 4:30 p.m. ET
Read more:
ADMA Biologics to Report Third Quarter 2024 Financial Results on November 7, 2024
Posted in Global News Feed
Comments Off on ADMA Biologics to Report Third Quarter 2024 Financial Results on November 7, 2024
Cronos Group Inc. to Hold 2024 Third Quarter Earnings Conference Call on November 12, 2024
Posted: October 30, 2024 at 2:42 am
TORONTO, Oct. 29, 2024 (GLOBE NEWSWIRE) -- Cronos Group Inc. (NASDAQ: CRON) (TSX: CRON) (“Cronos” or the “Company”) will hold its 2024 third quarter earnings conference call on Tuesday, November 12, 2024 at 8:30 a.m. ET. Cronos’ senior management team will discuss the Company’s financial results and will be available for questions from the investment community after prepared remarks.
Follow this link:
Cronos Group Inc. to Hold 2024 Third Quarter Earnings Conference Call on November 12, 2024
Posted in Global News Feed
Comments Off on Cronos Group Inc. to Hold 2024 Third Quarter Earnings Conference Call on November 12, 2024
Beyond Air® Schedules Second Fiscal Quarter 2025 Financial Results Conference Call and Webcast
Posted: October 30, 2024 at 2:42 am
GARDEN CITY, N.Y., Oct. 29, 2024 (GLOBE NEWSWIRE) -- Beyond Air, Inc. (NASDAQ: XAIR) (“Beyond Air” or the “Company”), a commercial stage medical device and biopharmaceutical company focused on harnessing the power of endogenous and exogenous nitric oxide (NO) to improve the lives of patients, today announced that it plans to report the financial results for the second quarter of its fiscal year 2025 ended September 30, 2024 on Monday, November 11, 2024 after the market closes.
Excerpt from:
Beyond Air® Schedules Second Fiscal Quarter 2025 Financial Results Conference Call and Webcast
Posted in Global News Feed
Comments Off on Beyond Air® Schedules Second Fiscal Quarter 2025 Financial Results Conference Call and Webcast
Neuronetics to Report Third Quarter 2024 Financial and Operating Results and Host Conference Call
Posted: October 30, 2024 at 2:42 am
MALVERN, Pa., Oct. 29, 2024 (GLOBE NEWSWIRE) -- Neuronetics, Inc. (NASDAQ: STIM), a medical technology company focused on designing, developing, and marketing products that improve the quality of life for patients who suffer from neurohealth disorders, announced that it plans to release third quarter 2024 financial and operating results prior to market open on Tuesday, November 12, 2024. The Company will host a conference call to review its results at 8:30 a.m. Eastern Time the same day.
See the original post here:
Neuronetics to Report Third Quarter 2024 Financial and Operating Results and Host Conference Call
Posted in Global News Feed
Comments Off on Neuronetics to Report Third Quarter 2024 Financial and Operating Results and Host Conference Call
Roivant to Report Financial Results for the Second Quarter Ended September 30, 2024 and Provide Business Update on Tuesday, November 12, 2024
Posted: October 30, 2024 at 2:42 am
BASEL, Switzerland and LONDON and NEW YORK, Oct. 29, 2024 (GLOBE NEWSWIRE) -- Roivant (Nasdaq: ROIV) today announced that it will host a live conference call and webcast at 8:00 a.m. ET on Tuesday, November 12, 2024, to report its financial results for the second quarter ended September 30, 2024, and provide a business update.
See the original post:
Roivant to Report Financial Results for the Second Quarter Ended September 30, 2024 and Provide Business Update on Tuesday, November 12, 2024
Posted in Global News Feed
Comments Off on Roivant to Report Financial Results for the Second Quarter Ended September 30, 2024 and Provide Business Update on Tuesday, November 12, 2024
Biomea Fusion Reports Third Quarter 2024 Financial Results and Corporate Highlights
Posted: October 30, 2024 at 2:42 am
REDWOOD CITY, Calif., Oct. 29, 2024 (GLOBE NEWSWIRE) -- Biomea Fusion, Inc. (“Biomea” or “the Company”) (Nasdaq: BMEA), a clinical-stage biopharmaceutical company dedicated to discovering and developing oral covalent small molecules to improve the lives of patients with diabetes, obesity, and genetically defined cancers, today reported third quarter 2024 financial results and corporate highlights.
More:
Biomea Fusion Reports Third Quarter 2024 Financial Results and Corporate Highlights
Posted in Global News Feed
Comments Off on Biomea Fusion Reports Third Quarter 2024 Financial Results and Corporate Highlights
